Abdolrahimi Safarali, Sanati Hamidreza, Fatahian Alireza
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
Res Cardiovasc Med. 2013 Nov;2(4):181-4. doi: 10.5812/cardiovascmed.12594. Epub 2013 Oct 28.
Data of the results from treatment of unprotected and protected LMCA diseases with PCI and stent implantations in our country were limited. Surgical therapy is considered as an standard care for patients with unprotected LMCA stenosis. This notion is based on some randomized and observational studies performed three decades ago which convincingly showed superiority of CABGs over medical therapy. Moreover, preliminary studies have shown that the use of DES for the treatment of unprotected LMCA diseases is associated with very favorable mid-term outcome, which is highly competitive with that of surgery, especially for ostial lesions.
This study sought to evaluate one year safety and effectiveness of PCI and stenting in LMCA disease.
We performed a one year clinical follow-up of any patients with LMCA disease "Protected and Unprotected" who underwent PCI and stenting (n = 40) with BMS (n = 17) or DES (n = 23) in Tehran's Rajaje and Lavasani hospitals from September 2010 to September 2011. The primary end points were all-cause mortality, and MACCE which consisted of the composite of death, MI, stroke, and target vessel revascularization, and the duration of hospitalization change the severity of angina pain and the function class of physical activity.
In the one year follow-up, the adjusted risk of death was 5% and the composite of death, MI, stroke and target vessel revascularization (MACCE) was 22%. In 94.7% the number of patients, the severity of angina pain were decreased, and in 92.5% of patients, the function class of physical activity has been improved. The duration of hospitalization was 4.38 ± 1.63 days which was less than that of CABGs.
For the treatment of protected and unprotected LMCA diseases, PCI with stent implantation is effective, and leads to decreasing the mortality and the death rate, MI, stroke, the severity of angina pain, and improving the function class of physical activity and tolerance.
我国关于经皮冠状动脉介入治疗(PCI)及支架植入术治疗无保护左主干病变和有保护左主干病变的结果数据有限。手术治疗被认为是无保护左主干狭窄患者的标准治疗方法。这一观念基于三十年前进行的一些随机和观察性研究,这些研究令人信服地表明冠状动脉旁路移植术(CABG)优于药物治疗。此外,初步研究表明,使用药物洗脱支架(DES)治疗无保护左主干病变具有非常良好的中期结果,与手术治疗结果具有高度竞争力,尤其是对于开口处病变。
本研究旨在评估PCI及支架植入术治疗左主干病变的一年安全性和有效性。
2010年9月至2011年9月,我们在德黑兰的拉贾耶医院和拉瓦萨尼医院对40例接受PCI及支架植入术的左主干病变患者(包括有保护和无保护病变)进行了为期一年的临床随访,其中17例使用裸金属支架(BMS),23例使用药物洗脱支架(DES)。主要终点为全因死亡率、主要不良心血管事件(MACCE),MACCE包括死亡、心肌梗死(MI)、中风和靶血管血运重建的综合情况,以及住院时间、心绞痛疼痛严重程度变化和体力活动功能分级。
在一年的随访中,校正后的死亡风险为5%,死亡、MI、中风和靶血管血运重建的综合情况(MACCE)为22%。在94.7%的患者中,心绞痛疼痛严重程度降低,在92.5%的患者中,体力活动功能分级得到改善。住院时间为4.38±1.63天,短于冠状动脉旁路移植术。
对于有保护和无保护的左主干病变的治疗,PCI及支架植入术是有效的,可降低死亡率、MI、中风、心绞痛疼痛严重程度,并改善体力活动功能分级和耐受性。